Ann: Immutep presents positive TACTI-mel melanoma trial data, page-3

This is pretty maj !! Patients with tumour shrinkage 17 (71%).
These individuals had almost no chance at survival and this bastard disease having spread to vital organs. Congratulations to the team at Immutep and associated trial staff. Regardless of what the market does initially, you have given hope to so many and to think that this is just one of multiple ponnies in our stable.

75% classified as M1c (associated with lowest probability of survival), 67% had lung metastasis, 50% had liver metastasis, 50% had elevated LDH (poor prognosis marker) and many had either a suboptimal response or disease progression with pembrolizumab treatment as a monotherapy.